Updates
Cures For Hair Loss 2023 - News Feed
A very good idea is to bookmark this article page in your browser or mobile browser for easy access on the latest hair loss cure and hair growth treatment news. This will allow you to check it easily for updates. If you are looking for a corresponding article from a past update, simply use the “Search” function on this site to locate the article. As always, thanks for reading and please share this information with all you feel would benefit from it!
New Androgen Receptor Degrader Enters The Field
AnHorn Medicines, a Taiwan-based biotech specializing in protein degradation, has recently announced plans to develop a hair loss therapeutic. The drug, AH-001, is categorized as an androgen receptor degrader, as opposed to the more familiar androgen receptor inhibitors. Head to the Articles page to read more about AnHorn Medicines current developments.
Can MicroRNA-205 Rejuvenate Human Hair Follicle Stem Cells?
A new study led by Rui Yi and fellows at Northwestern University has identified a specific miRNA (microRNA) which may play a role in hair follicle development. The study titled "MicroRNA-205 promotes hair regeneration by modulating mechanical properties of hair follicle stem cells" was published May 22, 2023 in PNAS. Apparently, hair follicle stem cells become stiff and rigid as they age which leads to a decrease in hair growth. The Northwestern group discovered that miRNA-205 is able to soften the stem cells, which also rejuvenated their hair growth-inducing properties.
Importantly, Yi was quoted to say "Because of the potential to deliver microRNA by nanoparticles directly into the skin, next we will test whether topically delivered miR-205 can stimulate hair growth first in mice. If successful, we will design experiments to test whether this microRNA can promote hair growth potentially in humans.” The study was conducted using genetically engineered mice.
Indian Biotech Develops New Hair Drug
A startup from India, Inovaugmet Research, is utilizing a novel drug screen platform to discover new drugs in dermatology. Luckily, their first candidate molecule happens to be aimed at treating androgenetic alopecia. Head to the Articles page to get the full scoop.
FOL-005 Phase 2a Trial Data Released By Follicum
After a hiatus of two years, Follicum, under new management, re-emerges to present new interesting data from their phase 2a study which was originally thought to miss its endpoint. Head to the Articles page for a full presentation from Follicum and a look at trichoscans from the trial, such as the page seen below.
Kintor US Phase 2 Trial Results Leading Towards US Phase 3 Trial
Check out the latest article with further details on how KX-826 aka pyrilutamide faired in a US phase 2 trial comprising male subjects, and also how the results compared to Kintor's China phase 2 trial of KX-826. Spoiler alert, the US phase 2 trial was successful, but it differed from the phase 2 results in China.
STEMON Promo Added
The first "promo" post has been added to the Promos page. These are short posts about companies, products, or ideas which meet the criteria to be shared on Follicle Thought, but may be in a different category than front page news. Stemon Inc has developed an interesting hair growth exosome technology which is not available for sale, but should likely be evaluated further in a small clinical study.
CosmeRNA Release Update
Following the release of a new CosmeRNA-themed article in the Korean press, there is reason to believe that CosmeRNA should finally be releasing next month. Head to to the Articles page to get the full scoop.
Kintor Doses First GT20029 Patient In Phase 2 Trial In China
Kintor Pharmaceutical's second drug for AGA, GT20029, which is an androgen receptor degrader drug and thought to be more advanced than KX-826/pyrilutamide, has entered into a phase 2 trial.
- The trial is a multi-center, double-blind, placebo-controlled study.
- It will enroll 180 male patients in China.
- The primary endpoint will be change from baseline in non-vellus target area hair counts (TAHC) after 12 weeks of treatment in comparison to placebo.
Industry Update Spring 2023
A new article was published today detailing some of the more interesting and obscure happenings in the hair growth treatment industry. Head to the home page or Articles page to read what's new.
Amplifica Eyes Trial This Year 2023
A new writeup which was featured on the UC Irvine News website titled "Huting for cures to hair loss" detailed the works of Dr. Maksim Plikus, a research scientist, and Dr. Natasha Mesinkovska, a dermatologist and research scientist. Dr. Plikus is well known for his work studying hairy moles which appear on human skin and for his co-founding of the biotech company Amplifica. Notably, the UCI article mentions that "Human trials on the company’s lead compound are expected to begin later this year." The company mentioned, of course, being Amplifica.